KRAS and neoplasm: Sweet-Cordero and colleagues assessed the enrichment of a KrasV12 tumour signature derived from a mouse cancer model in human tumours, observing an enrichment of the signature in human lung adenocarcinoma, but not specifically in KRAS mutants47.